Caner Saygin, MD
LightNews LightNews
banner
canersaygin.bsky.social
Caner Saygin, MD
@canersaygin.bsky.social
90 followers 38 following 10 posts
Leukemologist at the University of Chicago
Posts Replies Media Videos
Reposted by Caner Saygin, MD
anand-88-patel.bsky.social
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!

www.cancer.gov/research/par...
November 11, 2025 at 11:49 PM
Reposted by Caner Saygin, MD
uchicagocancer.bsky.social
In a new study, @canersaygin.bsky.social and colleagues show that TP53-mutant ALL is a high-risk, chemo-resistant subtype with poor survival, highlighting the need for tailored strategies.
ow.ly/lvwo50WHJIr
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults - Blood Cancer Journal
Blood Cancer Journal - Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
ow.ly
August 18, 2025 at 6:52 PM
Reposted by Caner Saygin, MD
leukemiaresearch.bsky.social
We’re thrilled to announce the 2025–2027 New Investigator Research Grant recipients—13 outstanding scientists from across the country who are pushing the boundaries of leukemia research.

Meet the 2025–2027 awardees: bit.ly/474sfGP

#LeukemiaResearch #ScientificDiscovery #FundingtheFuture
The Leukemia Research Foundation announces 2025-2027 research grant recipients
Northfield, IL - The Leukemia Research Foundation is pleased to announce the recipients of the 2025-2027 New Investigator Research Grant Program. Grants
bit.ly
July 31, 2025 at 9:16 PM
Reposted by Caner Saygin, MD
uchicagocancer.bsky.social
Proud of our cancer program for being #1 in Illinois for the 3rd year in a row!!

Learn more about our USNWR rankings at www.uchicagomedicine.org/forefront/ne...
U.S. News ranks University of Chicago Medical Center’s Cancer program best in state for third consecutive year - UChicago Medicine
The University of Chicago Medical Center earned national rankings in 10 adult specialties in the newly released U.S. News & World Report 2025-26 Best Hospitals list.
www.uchicagomedicine.org
July 29, 2025 at 5:50 PM
canersaygin.bsky.social
Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN.
Can we predict the risk for second blood cancer in myeloma pts?
Grateful for the collaboration with
@uchicagocancer.bsky.social myeloma program.
www.nature.com/articles/s41...
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma - Leukemia
Leukemia - Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
www.nature.com
July 16, 2025 at 8:08 PM